

3 April 2024

**Privatisation by way of scheme of arrangement**

**Disclosure of dealings in the shares of SciClone Pharmaceuticals (Holdings) Limited**

The Executive received the following disclosure of securities dealings pursuant to Rule 22 of the Hong Kong Code on Takeovers and Mergers:

Party	Date	Description of relevant securities	Nature of dealings	Purchase / Sale	Total number of shares involved	Total amount paid / received	Highest (H) prices paid / received	Lowest (L) prices paid / received
China International Capital Corporation Limited	2 April 2024	Other types of securities (e.g. equity swaps)	Closing / flattening / unwinding of proprietary positions arising from unsolicited client-driven dealings. I confirm this was done no later than the close of the morning trading session on the trading day following the originating client-driven dealing	Purchase	500,000	\$8,914,950.0000	\$17.8299	\$17.8299

		Other types of securities (e.g. equity swaps)	Closing / flattening / unwinding of proprietary positions arising from unsolicited client-driven dealings. I confirm this was done no later than the close of the morning trading session on the trading day following the originating client-driven dealing	Sale	500,000	\$8,914,950.0000	\$17.8299	\$17.8299
--	--	---	--	------	---------	------------------	-----------	-----------

End

Note:

China International Capital Corporation Limited is an exempt principal trader connected with the Offeror.

Dealings were made for its own account.

China International Capital Corporation Limited is ultimately owned by China International Capital Corporation Limited.